A Randomized, Double-Blind, Placebo-Controlled, Study of Efficacy and Safety of Pirfenidone in Patients With Fibrotic Hypersensitivity Pneumonitis
Latest Information Update: 11 Apr 2023
At a glance
- Drugs Pirfenidone (Primary)
- Indications Extrinsic allergic alveolitis; Fibrosis; Interstitial lung diseases
- Focus Therapeutic Use
- 07 Apr 2023 Results assessing the safety and effect of pirfenidone on disease progression in fibrotic hypersensitivity pneumonitis patients, published in the Thorax.
- 13 May 2021 Status changed from recruiting to completed.
- 26 Dec 2020 Planned number of patients changed from 44 to 40.